サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1400724

経口高分子製剤の世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2031年）- 適応症別、エンドユーザー別、地域別

Oral Macromolecular Formulation Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:

出版日
ページ情報
英文 158 Pages
納期
2～5営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
経口高分子製剤の世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2031年）- 適応症別、エンドユーザー別、地域別
出版日: 2023年12月22日
発行: Fairfield Market Research
ページ情報: 英文 158 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の経口高分子製剤の市場規模は目覚ましい成長を遂げており、2024年の売上は1,800万米ドルに達するとみられています。同市場は、年間平均成長率（CAGR）が7％と堅調に推移し、2031年末には推定評価額が約2,800万米ドルに達すると予測されています。

経口ドラッグデリバリーは、保存期間の延長、持続的な分布、免疫反応の強化など、固形製剤の可能性を含むその利点により、最も望ましい経路として浮上してきました。

注射針による損傷、痛み、針刺し損傷など、注射に伴う多くのリスクは、経口高分子製剤によって軽減することができます。米国では、毎年約385,000件の鋭利な怪我がヘルスケア従事者の間で発生しており、より安全な代替手段の重要性が強調されています。特に小児患者は、注射に伴う不快感から経口製剤に対する需要が高くなっています。

経口投与は、その非侵襲性、患者のコンプライアンス、使いやすさから、ドラッグデリバリーの最も一般的な方法となっています。経口投与は、高齢者や身体の弱い患者にとって特に重要であり、介助を必要とせずに薬剤を自己投与することができます。

経口高分子製剤は、その費用対効果の高さから、特に低所得地域において大きな需要があります。経口高分子製剤を専門とする研究者や受託製造業者は、斬新で実用的な1回投与製剤を提供することで、患者の生活を簡素化することに専心しています。

糖尿病患者はインスリン療法を必要とする可能性があるため、糖尿病の世界の増加が経口高分子製剤の需要を牽引しています。インスリンのような生体分子の経口製剤は、患者にとって不快で課題となりうる静脈内投与に比べ、潜在的な利点を提供します。

製薬メーカーは、酵素や酸による分解を克服することを目指し、生物製剤の経口投与を強化する様々な方法を積極的に模索しています。経口高分子製剤の吸収は生理的障壁に直面し、多くの高分子は消化酵素による急速な分解を受けやすいです。胃のpHも薬物吸収に影響を与えます。

米国市場は、技術的進歩、特許認可の増加、ドラッグデリバリーへのナノテクノロジー応用に関する地域的研究により成長を遂げています。ドイツ市場は、新規ドラッグデリバリーシステムに焦点を当てた研究開発活動が活発化しており、今後も成長が見込まれます。

当レポートでは、世界の経口高分子製剤市場について調査し、市場の概要とともに、適応症別、エンドユーザー別、地域別動向、および市場に参入する企業の競合動向などを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場の定義とセグメンテーション
  • 市場力学
  • バリューチェーン分析
  • ポーターのファイブフォース分析
  • COVID-19の影響分析
  • ウクライナとロシアの紛争の影響
  • 経済概要
  • PESTLE分析

第3章 世界の経口高分子製剤市場の見通し、2018年～2031年

  • 世界の経口高分子製剤市場の見通し、適応症別、金額（100万米ドル）、2018年～2031年
  • 世界の経口高分子製剤市場の見通し、エンドユーザー別、金額（100万米ドル）、2018年～2031年
  • 世界の経口高分子製剤市場の見通し、地域別、金額（100万米ドル）、2018年～2031年

第4章 北米の経口高分子製剤市場の見通し、2018年～2031年

第5章 欧州の経口高分子製剤市場の見通し、2018年～2031年

第6章 アジア太平洋の経口高分子製剤市場の見通し、2018年～2031年

第7章 ラテンアメリカの経口高分子製剤市場の見通し、2018年～2031年

第8章 中東・アフリカの経口高分子製剤市場の見通し、2018年～2031年

第9章 競合情勢

  • メーカーとエンドユーザー別のヒートマップ
  • 企業の市場シェア分析、2023年
  • 競合ダッシュボード
  • 企業プロファイル
    • Catalent, Inc
    • Diabetology Ltd
    • UPM Pharmaceuticals

第10章 付録

目次

The global Oral Macromolecule Formulation Market is experiencing remarkable growth, with revenues reaching US$ 18 million in 2024. Market analysts anticipate a steady Compound Annual Growth Rate (CAGR) of 7%, propelling the market to an estimated valuation of approximately US$ 28 million by the end of 2031.

Oral Delivery: The Preferred Route

Oral drug delivery has emerged as the most desirable route due to its advantages, including the potential for solid formulations with extended shelf life, continuous distribution, and enhanced immune response.

The numerous risks associated with injections, such as needle-related injuries, pain, and needle stick injuries, can be mitigated by oral macromolecule formulations. Approximately 385,000 sharp injuries occur among healthcare workers in the US each year, highlighting the importance of safer alternatives. Pediatric patients, in particular, have a high demand for oral formulations due to the discomfort associated with injections.

Growing Preference for Oral Administration

Oral administration has become the most popular method of drug delivery due to its non-invasiveness, patient compliance, and ease of use. It is especially crucial for elderly and physically fragile individuals, enabling self-administration of medications without the need for assistance.

Affordability and Accessibility

Oral macromolecule formulations are in significant demand, particularly in low-income regions, owing to their cost-effectiveness. Researchers and contract manufacturers specializing in oral macromolecule formulations are dedicated to simplifying patients' lives by offering novel and practical single-unit dosage forms.

Diabetes and Oral Macromolecular Formulations

The global rise in diabetes has driven the demand for oral macromolecular formulations, as diabetic patients may require insulin therapy. The oral formulation of biomolecules like insulin offers potential advantages over intravenous administration, which can be uncomfortable and challenging for patients.

Market Growth Drivers

Introduction of Novel Drug Delivery Systems: Pharmaceutical manufacturers are actively exploring various methods to enhance the oral administration of biologics, aiming to overcome enzymatic and acidic breakdown.

Challenges in Market Growth

Drawbacks and Poor Absorption: The absorption of oral macromolecule formulations faces physiological barriers, and many macromolecules are susceptible to rapid degradation by digestive enzymes. Gastric pH can also impact drug absorption.

Booming U.S. Market

The United States market is experiencing growth due to technological advancements, increased patent approvals, and regional research on nanotechnology applications for drug delivery.

Lucrative Market in Germany

Germany's market is set to advance with growing R&D activities focused on novel drug delivery systems.

China's Research Funding

The National Natural Science Foundation of China has funded various studies on the novel oral delivery of protein and peptide drugs, aligning with the booming market for these pharmaceuticals.

Competitive Landscape

Top pharmaceutical companies are forming strategic alliances with providers of oral macromolecule formulations, and the global market is expected to expand due to the rising demand for pharmaceutical outsourcing.

Key Companies Covered:

  • Catalent, Inc
  • Diabetology Ltd
  • UPM Pharmaceuticals

Market Segmentation

Indication:

  • Inflammatory Bowel Disorder

Crohn's Disease

Ulcerative Colitis

  • Diabetes
  • Others

End User:

  • Biopharmaceutical Companies
  • Academic and Research Institutes

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Oral Macromolecular Formulation Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Oral Macromolecular Formulation Market Outlook, 2018 - 2031

  • 3.1. Global Oral Macromolecular Formulation Market Outlook, by Indication, Value (US$ Mn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Inflammatory Bowel Disorder
        • 3.1.1.1.1. Crohn's Disease
        • 3.1.1.1.2. Ulcerative Colitis
      • 3.1.1.2. Diabetes
      • 3.1.1.3. Others
  • 3.2. Global Oral Macromolecular Formulation Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Biopharmaceutical Companies
      • 3.2.1.2. Academic and Research Institutes
  • 3.3. Global Oral Macromolecular Formulation Market Outlook, by Region, Value (US$ Mn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. North America
      • 3.3.1.2. Europe
      • 3.3.1.3. Asia Pacific
      • 3.3.1.4. Latin America
      • 3.3.1.5. Middle East & Africa

4. North America Oral Macromolecular Formulation Market Outlook, 2018 - 2031

  • 4.1. North America Oral Macromolecular Formulation Market Outlook, by Indication, Value (US$ Mn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Inflammatory Bowel Disorder
        • 4.1.1.1.1. Crohn's Disease
        • 4.1.1.1.2. Ulcerative Colitis
      • 4.1.1.2. Diabetes
      • 4.1.1.3. Others
  • 4.2. North America Oral Macromolecular Formulation Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Biopharmaceutical Companies
      • 4.2.1.2. Academic and Research Institutes
    • 4.2.2. BPS Analysis/Market Attractiveness Analysis
  • 4.3. North America Oral Macromolecular Formulation Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. U.S. Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 4.3.1.2. U.S. Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 4.3.1.3. Canada Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 4.3.1.4. Canada Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
    • 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Oral Macromolecular Formulation Market Outlook, 2018 - 2031

  • 5.1. Europe Oral Macromolecular Formulation Market Outlook, by Indication, Value (US$ Mn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Inflammatory Bowel Disorder
        • 5.1.1.1.1. Crohn's Disease
        • 5.1.1.1.2. Ulcerative Colitis
      • 5.1.1.2. Diabetes
      • 5.1.1.3. Others
  • 5.2. Europe Oral Macromolecular Formulation Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Biopharmaceutical Companies
      • 5.2.1.2. Academic and Research Institutes
    • 5.2.2. BPS Analysis/Market Attractiveness Analysis
  • 5.3. Europe Oral Macromolecular Formulation Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Germany Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 5.3.1.2. Germany Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.3.1.3. U.K. Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 5.3.1.4. U.K. Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.3.1.5. France Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 5.3.1.6. France Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.3.1.7. Italy Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 5.3.1.8. Italy Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.3.1.9. Turkey Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 5.3.1.10. Turkey Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.3.1.11. Russia Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 5.3.1.12. Russia Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.3.1.13. Rest of Europe Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 5.3.1.14. Rest of Europe Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Oral Macromolecular Formulation Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Oral Macromolecular Formulation Market Outlook, by Indication, Value (US$ Mn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Inflammatory Bowel Disorder
        • 6.1.1.1.1. Crohn's Disease
        • 6.1.1.1.2. Ulcerative Colitis
      • 6.1.1.2. Diabetes
      • 6.1.1.3. Others
  • 6.2. Asia Pacific Oral Macromolecular Formulation Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Biopharmaceutical Companies
      • 6.2.1.2. Academic and Research Institutes
    • 6.2.2. Others BPS Analysis/Market Attractiveness Analysis
  • 6.3. Asia Pacific Oral Macromolecular Formulation Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. China Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 6.3.1.2. China Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.3.1.3. Japan Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 6.3.1.4. Japan Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.3.1.5. South Korea Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 6.3.1.6. South Korea Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.3.1.7. India Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 6.3.1.8. India Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.3.1.9. Southeast Asia Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 6.3.1.10. Southeast Asia Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.3.1.11. Rest of Asia Pacific Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 6.3.1.12. Rest of Asia Pacific Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Oral Macromolecular Formulation Market Outlook, 2018 - 2031

  • 7.1. Latin America Oral Macromolecular Formulation Market Outlook, by Indication, Value (US$ Mn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Inflammatory Bowel Disorder
        • 7.1.1.1.1. Crohn's Disease
        • 7.1.1.1.2. Ulcerative Colitis
      • 7.1.1.2. Diabetes
      • 7.1.1.3. Others
  • 7.2. Latin America Oral Macromolecular Formulation Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. Biopharmaceutical Companies
      • 7.2.1.2. Academic and Research Institutes
    • 7.2.2. BPS Analysis/Market Attractiveness Analysis
  • 7.3. Latin America Oral Macromolecular Formulation Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Brazil Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 7.3.1.2. Brazil Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 7.3.1.3. Mexico Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 7.3.1.4. Mexico Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 7.3.1.5. Argentina Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 7.3.1.6. Argentina Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 7.3.1.7. Rest of Latin America Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 7.3.1.8. Rest of Latin America Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Oral Macromolecular Formulation Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Oral Macromolecular Formulation Market Outlook, by Indication, Value (US$ Mn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Inflammatory Bowel Disorder
        • 8.1.1.1.1. Crohn's Disease
        • 8.1.1.1.2. Ulcerative Colitis
      • 8.1.1.2. Diabetes
      • 8.1.1.3. Others
  • 8.2. Middle East & Africa Oral Macromolecular Formulation Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Biopharmaceutical Companies
      • 8.2.1.2. Academic and Research Institutes
    • 8.2.2. BPS Analysis/Market Attractiveness Analysis
  • 8.3. Middle East & Africa Oral Macromolecular Formulation Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. GCC Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 8.3.1.2. GCC Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 8.3.1.3. South Africa Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 8.3.1.4. South Africa Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 8.3.1.5. Egypt Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 8.3.1.6. Egypt Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 8.3.1.7. Nigeria Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 8.3.1.8. Nigeria Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 8.3.1.9. Rest of Middle East & Africa Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 8.3.1.10. Rest of Middle East & Africa Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Manufacturer vs by End User Heatmap
  • 9.2. Company Market Share Analysis, 2023
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Catalent, Inc
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Development
    • 9.4.2. Diabetology Ltd
      • 9.4.2.1. Company Overview
      • 9.4.2.2. Product Portfolio
      • 9.4.2.3. Financial Overview
      • 9.4.2.4. Business Strategies and Development
    • 9.4.3. UPM Pharmaceuticals
      • 9.4.3.1. Company Overview
      • 9.4.3.2. Product Portfolio
      • 9.4.3.3. Financial Overview
      • 9.4.3.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations